Biotoxtech KRX:086040KOSDAQ

바이오톡스텍 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked6since Sep 11

In Q3 2026, Biotoxtech reported revenue of ₩16.1bn, up 35.0% year on year, and operating profit of ₩579m. Biotoxtech (바이오톡스텍) appeared in 0 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 4 with 1 article.

Filing signals Turnaround Revenue +30% Insider buying Major holder adding Screener

Biotoxtech at a glance from DART filings

Results trend
Operating profit in 1 of the last 4 quarters; Q3 2026 operating profit of ₩579m swung to a profit from a loss in the previous quarter.
Ownership changes
18 5%-holder and insider ownership reports in the past 120 days (17 increases, 1 decreases).

Figures the company filed on DART, grouped by ATS View. Not a buy or sell call; see the cards below and the DART originals.

Biotoxtech today: up or down?

No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.

Upcoming dates as filed

  • Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026

Dates Biotoxtech stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.

Biotoxtech quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q3 2026₩16.1bn+35.0%₩579m
margin 3.6%
−₩1.3bn
Q2 2026₩14.5bn+50.3%−₩182m
margin −1.3%
−₩6.9bn
Q1 2026₩11.9bn+5.5%−₩1.8bn
margin −15.4%
−₩2.7bn
Q4 2025 derived₩14.2bn+24.7%−₩98m
margin −0.7%
−₩2.0bn
Q3 2025₩11.9bn+7.0%−₩1.4bn
margin −11.5%
₩4.5bn
Q2 2025₩9.6bn-1.9%−₩1.9bn
margin −20.0%
−₩2.0bn
Q1 2025₩11.2bn+25.1%−₩1.4bn
margin −12.6%
−₩2.1bn
Q4 2024 derived₩11.4bn+34.0%−₩1.4bn
margin −12.3%
−₩4.0bn

Biotoxtech ranks #1228 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Biotoxtech top stories 2 weeks, by number of outlets

  1. 1

Latest Biotoxtech news Korean headlines